CTHIn ForceLegislation
National Health (Pharmaceutical Benefits) Regulations 2017
81Step 11—weighted average disclosed price for listed brand of pharmaceutical item
Start here
Get a plain-English read of 81
Turn the raw legal text into a practical explanation grounded in National Health (Pharmaceutical Benefits) Regulations 2017.
#### 81 Step 11—weighted average disclosed price for listed brand of pharmaceutical item
(1) Work out the weighted average disclosed price of the listed brand of the pharmaceutical item for the data collection period.
(2) The weighted average disclosed price of the listed brand of the pharmaceutical item is the average approved ex‑manufacturer price for the listed brand reduced by the weighted average percentage difference for all related brands (see step 10).
(3) However, if the pricing quantity of the listed brand of the pharmaceutical item on the final day is different from the pricing quantity of the listed brand on the relevant day, the weighted average disclosed price is:

where:
> PQ1 means the pricing quantity of the listed brand on the final day.
> PQ2 means the pricing quantity of the listed brand on the relevant day.
> WR means the average approved ex‑manufacturer price for the listed brand reduced by the weighted average percentage difference for all related brands (see step 10).
> Note: See section 99ADHA of the Act for price reductions for brands listed after the end of the data collection period.
(4) This section has effect subject to section 82.